---
id: 2016-01-01--fentanyl-overtakes-prescription-opioids
title: Illicit Fentanyl Overtakes Prescription Opioids as Leading Cause of Overdose Deaths
date: '2016-01-01'
importance: 9
actors:
  - Drug Enforcement Administration
  - Centers for Disease Control and Prevention
  - Illicit Fentanyl Suppliers
tags:
  - opioid-crisis
  - fentanyl
  - synthetic-opioids
  - public-health
  - unintended-consequences
status: confirmed
sources:
  - title: Drug Overdose Deaths - Facts and Figures
    url: https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates
    publisher: National Institute on Drug Abuse
    date: '2024-01-01'
    tier: 1
  - title: Are fentanyl overdose deaths rising in the US?
    url: https://usafacts.org/articles/are-fentanyl-overdose-deaths-rising-in-the-us/
    publisher: USAFacts
    date: '2023-01-01'
    tier: 2
  - title: Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017
    url: https://www.cdc.gov/mmwr/volumes/67/wr/mm675152e1.htm
    publisher: CDC MMWR
    date: '2018-12-21'
    tier: 1
---

In 2016, illicit fentanyl and other synthetic opioids overtook prescription opioids as the leading cause of opioid overdose deaths in the United States, marking a deadly transition in the opioid epidemic. This shift represented the catastrophic unintended consequence of belated efforts to restrict prescription opioid access without providing adequate addiction treatment—users addicted to prescription pills transitioned to far more dangerous illicit drugs.

## Third Wave of Opioid Epidemic

Since 2016, the majority of overdose deaths have been linked to synthetic opioids, primarily illicitly manufactured fentanyl and fentanyl analogs. The 63,632 drug overdose deaths in 2016 represented a 21.4% increase from 2015, with two-thirds involving an opioid and the largest increase occurring among deaths involving synthetic opioids other than methadone.

Since 2013, the rate of synthetic opioid overdose deaths increased by approximately 87% per year. By 2018, the National Institute on Drug Abuse announced that synthetic opioids, primarily fentanyl, had become the most common substances involved in opioid overdose fatalities, exceeding the rate of prescription opioids.

## Why Users Transitioned to Fentanyl

Multiple factors drove the shift from prescription opioids to illicit fentanyl:

**Prescription Restrictions:** Following the CDC's 2016 prescribing guidelines and increased regulatory scrutiny, access to prescription opioids became more restricted. Many people already addicted to prescription pills lost access to legal supplies.

**OxyContin Reformulation:** Purdue's 2010 reformulation made OxyContin harder to crush and inject, pushing users toward alternatives like heroin and fentanyl.

**Economic Factors:** Illicit fentanyl cost less than prescription opioids on the street, making it economically attractive to users and dealers.

**Supply Chain:** Mexican drug trafficking organizations and Chinese chemical manufacturers began mass-producing illicit fentanyl, flooding U.S. markets with cheap, potent synthetic opioids.

## Fentanyl's Deadly Potency

Fentanyl is approximately 50-100 times more potent than morphine and 50 times more potent than heroin. This extreme potency created deadly consequences:
- Minuscule dosing errors cause fatal overdoses
- Users cannot reliably assess dosage
- Street drugs sold as heroin often contain fentanyl without buyers' knowledge
- Naloxone (overdose reversal drug) sometimes insufficient for fentanyl overdoses
- Analog compounds (carfentanil, etc.) even more potent

## Prescription Epidemic Created Fentanyl Market

The fentanyl crisis represents a direct consequence of the prescription opioid epidemic that began in 1996:

1. **Purdue's marketing (1996-2007)** created millions of Americans addicted to prescription opioids
2. **Belated crackdowns (2007-2016)** restricted prescription access without adequate treatment
3. **Addicted users transitioned (2010-2016)** to heroin, then illicit fentanyl
4. **Deaths accelerated (2016-present)** as fentanyl's potency caused overdose spike

Had Purdue never launched its fraudulent OxyContin marketing campaign, the subsequent fentanyl crisis would likely never have developed this market of opioid-addicted Americans vulnerable to even deadlier synthetic alternatives.

## Regulatory Failures Continue

The fentanyl crisis revealed continued regulatory inadequacies:
- Insufficient border controls to prevent fentanyl smuggling
- Failure to regulate precursor chemicals from China
- Inadequate resources for addiction treatment
- Limited access to overdose reversal medication
- Insufficient harm reduction programs (needle exchanges, supervised injection sites)

## Death Toll Acceleration

Fentanyl-involved deaths rose dramatically:
- 2015: ~9,600 synthetic opioid deaths
- 2016: ~19,400 synthetic opioid deaths (doubled in one year)
- 2017: ~28,400 synthetic opioid deaths
- 2020: ~56,500 synthetic opioid deaths
- 2023: Over 70,000 synthetic opioid deaths

The acceleration demonstrated how transitioning from prescription opioids to illicit fentanyl made the crisis far deadlier, even as prescription opioid deaths plateaued or declined.

## Unintended Consequences of Inadequate Policy

The fentanyl crisis exemplifies catastrophic policy failure:

**Wrong Approach:** Restricted prescription access without providing treatment, pushing addicted users to more dangerous alternatives.

**Right Approach:** Would have been aggressive treatment expansion, harm reduction programs, and addressing the addiction crisis created by pharmaceutical companies rather than simply cutting off supply.

The result: deaths increased rather than decreased as users transitioned to more dangerous drugs.

## Corporate Accountability Vacuum

No pharmaceutical executives faced criminal charges for creating the prescription opioid epidemic that led to the fentanyl crisis. The accountability failures enabled:
- Purdue executives avoided prison despite guilty pleas
- Sackler family retained billions in extracted wealth
- Distributors paid settlements but executives faced no prosecution
- Pattern of impunity established for pharmaceutical industry

Had executives faced prison in 2007, the industry might have been deterred from continuing aggressive opioid marketing, potentially preventing the later fentanyl crisis.

## Treatment Infrastructure Inadequacy

As fentanyl deaths surged, treatment infrastructure remained grossly inadequate:
- Months-long waitlists for addiction treatment programs
- Insufficient medication-assisted treatment availability
- Many treatment programs refused medication-assisted treatment
- Insurance barriers limited access to care
- Rural areas especially underserved

The treatment gap meant many people who wanted help could not access it, leaving them vulnerable to fentanyl-involved overdoses.

## Criminal Drug Market Evolution

Illicit fentanyl transformed the illegal drug market:
- Dealers could produce synthetic opioids without poppy cultivation
- Extreme potency meant easier smuggling (smaller quantities)
- Profit margins higher than traditional heroin
- Contamination of other drugs (cocaine, methamphetamine) with fentanyl increased deaths among non-opioid users

## Pattern: Crisis Evolution Outpaced Response

At every stage, the policy response lagged years behind the crisis evolution:
- **1996-2007:** Fraudulent marketing unchecked for 11 years
- **2007-2016:** Inadequate prosecution response after guilty plea
- **2010-2016:** Prescription restrictions without treatment expansion
- **2016-present:** Fentanyl crisis met with inadequate resources and continued accountability failures

## Preventable Catastrophe

The fentanyl crisis was preventable at multiple intervention points:
- FDA could have required adequate evidence before approving OxyContin claims (1995)
- DOJ could have criminally prosecuted executives after 2007 guilty plea
- CDC could have issued prescribing guidelines before 2016
- Congress could have funded massive treatment expansion when crisis emerged
- Regulators could have prevented pharmaceutical companies from creating addiction epidemic

Instead, each failure compounded previous failures, creating cascading catastrophe that killed hundreds of thousands and continues accelerating today.

This transition from prescription opioids to illicit fentanyl demonstrates how inadequate corporate accountability and belated regulatory responses to pharmaceutical industry misconduct can trigger even deadlier secondary crises, multiplying the human toll of initial regulatory capture and corporate impunity.
